SYS-LIFE postdoctoral programme announced the selected fellows and their projects for the first call of the programme. The next call will be opened during autumn 2024.
A large international study conducted at the University of Turku in Finland found that most adolescents do not seek professional help even when they have a high level of mental health problems. This unmet need was prevalent across all eight Asian and European countries involved in this study but especially in lower-income countries.
Where top-level research is conducted, the patients also receive first-rate care. Patients’ interest is also based on this same logic when they are selecting a hospital. In the joint orthopaedic research unit of the University of Turku and Turku University Hospital, new and improved methods are developed, which in turn benefits the patients of Tyks Orto – a top-level medical clinic focusing on injuries and diseases of the body's musculoskeletal system. The latest research results from this spring are interesting also to implant manufacturers all over the world.
The new technology, which was created at the University of Turku and developed by the company CardioSignal, uses a smartphone to analyse heart movement and detect heart failure. The study involved five organisations from Finland and the United States.
Research Flagship Centre INVEST is commissioning an international external assessment of its activities and future options as the first Finnish Flagship. The assessment will help INVEST and its host organisations to decide on the future of its activities after the end of the current flagship period.
SYS-LIFE postdoctoral research programme invites applications for 22 postdoctoral researcher positions at the University of Turku, Finland, for a fixed-term period of three years. The first call for applications opened on 5 December and closes on 31 January 2023.
Cutaneous squamous cell carcinoma (cSCC), also known as the squamous cell carcinoma of the skin, is the most common form of metastatic skin cancer. The incidence of cSCC is increasing worldwide with millions of new cases diagnosed each year. The prognosis of metastatic cSCC is poor as there are currently no effective targeted treatments available. New study conducted at the University of Turku, Finland, shows that plixorafenib, a new drug developed for treating melanoma and lung cancer, can also stop the progression of cutaneous squamous cell carcinoma.